MedPath

Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Procedure: Sputum induction
Procedure: Skin prick test
Other: Questionnaires
Registration Number
NCT02332122
Lead Sponsor
Wim Janssens
Brief Summary

A single center case-control study with 100 COPD patients will be organized to compare patients with and without bronchiectasis with regard to the presence of Aspergillus in sputum samples, Aspergillus sensitization and vitamin D. Induced sputum samples will be optimized for culture, Aspergillus galatomannan analysis and RT-PCR.

This study is part of a larger project in which we assume that chronic respiratory infection by Aspergillus fumigatus and the accompanying immune response play an important role in the development of bronchiectasis in COPD. We suspect that this mechanism is controlled by vitamin D and it fails by suppression of the vitamin D receptor by Aspergillus fumigatus.

The present study is designed by the Laboratory of pneumology and will be conducted in collaboration with the Laboratory of clinical bacteriology and mycology of the Catholic University of Leuven.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Established diagnosis of COPD by medical doctor (based on clinical history or pulmonary function test)
  • Smoking history of at least 10 pack-years
  • CT Thorax available for assessment of bronchiectasis
  • FEV1 >= 30%
Exclusion Criteria
  • Mechanical or non-invasive ventilation
  • Other main respiratory diagnosis other than COPD
  • Active mycobacterial disease
  • Immunosuppression other than steroids
  • Active cancer treatment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
COPD patients without bronchiectasisSkin prick testAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
COPD patients without bronchiectasisQuestionnairesAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
COPD patients with bronchiectasisSputum inductionAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
COPD patients with bronchiectasisSkin prick testAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
COPD patients with bronchiectasisQuestionnairesAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
COPD patients without bronchiectasisSputum inductionAll patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires
Primary Outcome Measures
NameTimeMethod
Bronchiectasisimmediate
Secondary Outcome Measures
NameTimeMethod
Vitamin Dimmediate
Prevalence of Aspergillus sensitizationmax 12weeks
Prevalence of Aspergillus isolation in sputummax 12weeks

Trial Locations

Locations (1)

UZ Gasthuisberg

🇧🇪

Leuven, Vlaanderen, Belgium

© Copyright 2025. All Rights Reserved by MedPath